Zykadia (ceritinib)

pill
100 % legal and regulated
Secured logistics globally
24/7 track & trace delivery
Safe payment by bank transfer or credit card
5/5
Patients and doctors who have ordered medicines from us have given us a 5 out of 5 star rating for our service

Enquire now
or read
We are registered as an independent intermediary for medicines with the Dutch Ministry of Health

Zykadia (ceritinib)

How to buy Zykadia: You can order Zykadia (ceritinib) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient's country. TheSocialMedwork - helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Novartis
Disease Lung Cancer
Indication ALK-positive NSCLC
Mode of Action Kinase inhibitor (targeted therapy)
Approval Status EMA approved (EU); FDA approved (USA); TGA approved (AUS)
CAS Number 1032900-25-6
HS Code 29331990
Strength 150 mg

Who is ceritinib for?

Zykadia (ceritinib) is indicated for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) [1][2][3]. While the FDA and EMA recommend it for first-line treatment [1][2], the TGA recommend it for patients whose disease has progressed on, or who are intolerant of crizotinib [3].

Recommended dose

Complete information about Zykadia (ceritinib) dosage and administration can be found here: [1][2][3].
The standard dosage is:
  • 750 mg  (5 capsules) orally once daily.
  • Taken at least 1 hour before or at least 2 hours after a meal.
Consult your treating doctor for personalised dosing.

What is ceritinib and how does it work?

Zykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with metastatic ALK-positive NSCLC [1][2][3].
Mutations of the ALK gene can occur in several different types of cells, including lung cells, and can result in the development of a tumour [4]. ALK gene mutations occur in 2 to 7 % of patients with NSCLC [5]. Ceritinib is an ALK-inhibitor, which acts by inhibiting the activity of the ALK protein, and may thus prevent ALK-positive NSCLC-cells from growing and spreading [6].

What is ceritinib's approval status?

Zykadia (ceritinib) was approved by:
  • FDA (USA) on April 4, 2014 [5]  with an accelerated approval for ALK-positive NSCLC in patients whose disease has progressed on or who are intolerant of crizotinib; and on May 26, 2017 [7] with regular approval for previously untreated ALK-positive metastatic NSCLC
  • EMA (EU) on May 6, 2015 [6]
  • TGA (AUS) on March 3, 2016 [3]
as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
The EMA and TGA approvals of ceritinib for ALK-positive NSCLC in previously treated patients were based on two main global, multicentre, open-label, single-arm studies (study X2101 and study A2201) which involved in total 303 patients in whom the disease progressed despite previous treatment with crizotinib (Xalkori). In both studies, the medicine was not compared with any other treatment. The overall response rate (ORR) was 56.4 % [95 % CI: 48.5, 64.2] in Study X2101 and 37.1 % [95 % CI: 29.1, 45.7] in study A2201. The median duration of response (DoR) was 8.3 months [95 % CI: 6.8, 9.7]  in Study X2101 and 9.2 months [95 % CI: 5.6, NE] in study A2201. The median progression-free survival (PFS) was 6.9 months [95 % CI: 5.6, 8.7] in Study X2101 and 5.7 months [95 % CI: 5.3, 7.4] in study A2201 [2][3].
The FDA and EMA approval of ceritinib for ALK-positive NSCLC in previously untreated patients was based on an open-label, randomized, active-controlled multicenter Study (ASCEND-4) involving 376 previously untreated ALK-positive NSCLC patients who were treated with Zykadia (ceritinib) or chemotherapy. The median PFS was 16.6 months [95 % CI: 12.6, 27.2] in the ceritinib arm and 8.1 months [95 % CI: 5.8, 11.1] in the chemotherapy arm. The ORR, was 73 % [95 % CI: 66, 79] and 27 % (95 % CI: 21, 34) in the ceritinib and chemotherapy arms, respectively. The median DoR was 23.9 months [95 % CI: 16.6, not estimable] and 11.1 months [95 % CI: 7.8, 16.4] in the ceritinib and chemotherapy arms, respectively. In patients with measurable central nervous system (CNS) lesions on baseline brain scans, the confirmed overall intracranial response rate (OIRR) was 57 % [95 % CI: 37, 76] in the ceritinib arm and 22 % [95 % CI 9, 42] in the chemotherapy arm. The median CNS response duration was 16.6 months [95 % CI: 8.1, NE] and not estimable [95 % CI: 1.5, NE] in the ceritinib and chemotherapy arms, respectively [1][2][7].
References
[1] Summary of Product Characteristics [FDA]: Zykadia (ceritinib), Novartis, May 2017.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205755s009lbl.pdf
[2] Summary of Product Characteristics [EMA]: Zykadia (ceritinib), Novartis, Mar. 2017.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003819/WC500187504.pdf
[3] Summary of Product Characteristics [TGA]: Zykadia (ceritinib), Novartis, Mar. 2016.
https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2016-PI-01610-1
[4] FDA News Release: FDA approves new oral therapy to treat ALK-positive lung cancer, 11/12/2015.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm
[5] Drugs.com. FDA approves Zykadia, Apr. 2014.
https://www.drugs.com/newdrugs/fda-approves-zykadia-ceritinib-metastatic-non-small-cell-lung-cancer-4035.html
[6] EMA. Human Medicines: Zykadia (ceritinib), 04/06/2015, (last update: 23/03/2017), cited on 20/06/2017.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003819/human_med_001860.jsp&mid=WC0b01ac058001d124
[7] FDA. Approved Drugs: FDA broadens ceritinib indication to previously untreated ALK-positive metastatic NSCLC, 26/05/2017.
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560873.htm








"TheSocialMedwork helped us to get the medicine, which was not accessible for us, in the shortest possible time."

- Haoyu, China.
Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM



Share our website

Follow us


DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision. Privacy Policy / Terms and Conditions
Our service uses cookies.